^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Lymphoplasmacytic Lymphoma |
| Drug: | iopofosine I-131 (CLR 131) (DNA inhibitor, Ionizing radiation emitter) |
| Direction: | Sensitive |
Evidence:
Title:
Cellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia
Published date:
05/26/2020
Excerpt:
...Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CLR 131 in lymphoplasmacytic lymphoma (LPL)/Waldenstrom’s macroglobulinemia (WM) in patients having received two prior treatment regimens or more.
